Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report

Population sampling

Between March 1^st and August 12^th, 2020, 11,622 patients were tested for SARS-CoV-2 by rt-PCR (Figure S1). Of these, 643 patients had at least one positive test (5.5% positivity) and 176 patients had at least two positive samples. Time from first positive to last positive was determined as the shedding duration (Figure 1A). The median (interquartile range) shedding duration was 12.1 (6.4, 24.7) days, with a positively skewed distribution (kurtosis = 10.7). Shedding was <59 days in 95% of patients, and was >75 days in only two patients. Re-positivity was observed in 43 patients (Figure 1B) with patterns suggesting: 1) inadequate sampling technique, 2) assay limitations with the Ct result hovering at the limit of detection, 3) prolonged shedding, potentially combined with either of the former, or 4) reinfection. The patient with the longest duration between negative rt-PCR and re-positive was enrolled in an observational study to distinguish between these possibilities.

• Download figure
• Open in new tab

Figure 1: Population viral RNA shedding from patients with COVID-19

Panel A: Distribution of shedding duration in patients who had at least 2 positive SARS-CoV-2 PCR tests. The shedding duration was calculated as the time from first positive sample to last positive sample. In the histogram (n=176), the proportion of patients is plotted as density on the y-axis and shedding duration (in days) is on the x-axis. Panel B: Time course of SARS-CoV-2 shedding in patients (n=43) who had “re-positive” pattern (repeat SARS-CoV-2 PCR positive after negative testing in patients with initially PCR-confirmed COVID-19, i.e. a positive-negative-positive pattern). In the spaghetti plot, semi-quantitative real-time PCR expressed in cycle thresholds (Ct) is plotted on the y-axis and time course in days from first positive to last positive is on the x-axis. Ct is the average result of E & N2 genes except where one target was undetectable and then Ct was set to value of single positive target. Ct range: 14.9 – 44.0. Negative (undetectable) results are set to Ct = 50 for purposes of display. UD = undetectable. Red stars mark possible reinfections due to low CT value at re-positive, or long duration since last positive PCR, respectively.

Case Study

InCoV139 is a sexagenarian (age between 60 – 69), who resides in a skilled nursing facility (SNF) and has a history of severe emphysema (FEV1 34% predicted) on home oxygen, and hypertension. When hospitalized in early March for severe COVID-19 pneumonia, symptoms included fever, chills, productive cough, dyspnea and chest pain. The patient reported exposure to a SNF employee recently returned from the Philippines with respiratory infection. Auscultation revealed diffuse wheezing and dullness at the left base and chest X-ray showed hyperinflation and bibasilar infiltrates. Unstable atrial fibrillation ensued and was treated with cardioversion and anticoagulation. The patient received treatment with supportive care consisting of supplemental oxygen, steroids and multimodal inhaled therapies for chronic obstructive pulmonary disease. The patient returned to the SNF after testing negative on days 39 and 41 of hospitalization.

InCoV139 remained isolated from family and visitors, interacting only with SNF residents and staff. After moving to a different facility, the patient described exposure to residents at the new facility who were coughing. On day 140 after the first positive SARS-CoV-2 PCR, the patient returned to the ER with dyspnea, reporting 2 weeks of dry cough and weakness. SARS-CoV-2 PCR was repeatedly positive on days 1 and 6 of re-hospitalization (day 14 and day 19 after reinfection date of symptoms onset). Compared to admission in March, the patient was less severely ill in July, by physiologic, laboratory and radiographic parameters, with higher Ct values (Table 1, Figure S2). Status returned to baseline after treatment with remdesivir and dexamethasone.

Viral Sequencing and Phylogenetic Analysis

Comparison of InCoV139 sequences from March and July revealed 10 high confidence intra-host single nucleotide variants (iSNVs) of which 5 type the March sequence to clade 19B, and 5 type the July sequence to 20A. The InCoV139-March sequence (Genbank: MT252824) shares the canonical mutations (C8782T and T28144C) which define clade 19B and distinguish it from the original clade 19A, Wuhan-Hu-1 reference strain (Genbank: NC_045512.2). InCoV139-March additionally shares C18060T with the first US case WA1 (Genbank: MN985325), which was circulating in Asia and introduced via a traveler returning from Wuhan, China to the Puget Sound area north of Seattle in mid-January.¹⁷ InCoV139-March diverges from WA1 by 2 other mutations suggesting evolution via community spread in the ensuing 7 weeks from diagnosis of WA1 to diagnosis of InCoV139-March. Conspicuously, the July sequence (InCoV139-July) harbors none of the canonical mutations defining clade 19B and instead shares the canonical mutations defining clade 20A (C3037T, C14408T and A23403G), 1 canonical mutation of clade 20C (G25563T), as well as 1 other 20A mutation. Importantly, present in InCoV139-July (but not in InCoV139-March) is the A23403G mutation, which confers the D614G amino acid change in spike protein, and defines the SARS-CoV-2 strain with greater replicative fitness, introduced separately to the US East Coast via Europe.¹⁸ As indicated in the phylogeny (Figure 2), the iSNVs (Table S1) clearly define 2 genetically distinct viruses which evolved separately from a common ancestor in early divergent events.

• Download figure
• Open in new tab

Figure 2: Phylogram of SARS-CoV-2 Isolates in Washington State

Phylogeny of SARS-CoV-2 in Washington State, including contextual sequences, and the pairs of reported reinfection cases from Hong Kong and Nevada. Sequences are colored by clade, as designated by NextClade as follows: 19A: royal blue, 19B: teal, 20A: green, 20B: yellow and 20C: orange. The pair of reinfection cases from InCoV139 (red) are the sample in clade 19B on March 6 from the initial infection and the sample in Clade 20A on July 29 from the reinfection. The initial Hong Kong sample was in Clade 19A and the reinfection sample in 20A; both Nevada samples were in Clade 20C. Sequences are labeled as per the GISAID nomenclature, with edits for readability and information on each sequence is provided (Table S2). An interactive version of this tree is included as supplemental material.

Anti-SARS-CoV-2 Antibody Response

Plasma samples from InCoV139 in July were measured for anti-SARS-CoV-2 antibodies (Figure 3). IgG antibodies against RBD, spike and nucleocapsid were detected, with low optical density compared to positive control,¹³ and showed a decreasing trend from day 14 to 42 after reinfection symptoms onset. IgM was weakly positive to spike, but undetectable to RBD and nucleocapsid. IgA specific for spike and nucleocapsid, but not RBD, was detected at low levels on day 14 to 21. Anti-spike and anti-RBD IgA showed a surprising increase by day 42, confirmed in replicate and titration experiments (Figure S3). IgG subclass analysis revealed that the patient’s RBD-specific IgG response consisted of low levels of IgG3, without detectable IgG1, despite having both IgG1 and IgG3 specific for spike and nucleocapsid proteins with decreasing trend (Figure S4). Antibodies blocking ACE2-RBD binding were undetectable at day 14, suggesting a lack of potentially protective antibodies, and increased by day 42 (Figure 3). At day 14 and 42, nAb titers (IC50) were 1:260 and 1:382 against D614 (Wuhan) pseudovirus, and were 1:449 and 1:1168 against a mutated D614G pseudovirus, showing differential increase of nAb to D614G pseudovirus compared to the Wuhan strain (Figures 3D and S5).

• Download figure
• Open in new tab

Figure 3. Anti-SARS-CoV-2 serologies and neutralizing antibodies

Plasma samples were analyzed by ELISA at a 1:100 dilution for the presence of IgG, IgA and IgM antibodies binding to the SARS-CoV-2 spike (Panel A), nucleocapsid (Panel B), and RBD (Panel C) antigens. Panel D shows the results of testing for antibodies that block the binding of ACE2 to RBD, carried out with a 1:10 dilution of plasma (left y-axis). Pseudovirus neutralizing antibodies were detected with in vitro cell culture assay with D614 (Wuhan) pseudovirus and D614G pseudovirus (right y-axis). For all panels, time on the x-axis indicates days after symptom onset during SARS-CoV-2 reinfection. Plasma pools from SARS-CoV-2 pre-pandemic healthy blood donors and from primary infection COVID-19 patients were used as negative and positive quality control (QC), respectively. The dotted line is the cutoff value for a positive result for each assay, determined as described in the Supplemental Methods. All samples were tested in duplicate wells, and mean OD values are shown. Results are shown from one of two replicate experiments carried out on different days.

Antibody and B-Cell Receptor Repertoires

B cells were evaluated in peripheral blood at day 14 and 18 after reinfection by NGS of IGH genes of all isotypes (Figure 4A). Healthy human peripheral blood shows a predominance of naíve B cells expressing IgM and IgD without somatic hypermutation, and memory B cells with mutated class-switched antibodies. In contrast, the acute response to primary SARS-CoV-2 infection features large polyclonal expansions of recently class-switched, low somatic hypermutation B cells expressing IgG subclasses and, to a lesser degree, IgA subclasses,¹⁹ as shown in longitudinal samples from an unrelated patient at day 9 (prior to seroconversion) and day 13 (after seroconversion) after primary infection with SARS-CoV-2. In contrast, clones with low somatic hypermutation did not emerge by day 14 or 18 after reinfection in patient InCoV139 (Figure 4A). Parallel analysis by single-B cell immunoglobulin sequencing revealed elevated frequencies of IgA-expressing B cells, particularly IgA2-expressing cells (Figure 4B).

• Download figure
• Open in new tab

Figure 4. B cell repertoire responses

Panel A: Peripheral blood B cell IGH gene repertoires from peripheral blood mononuclear cell RNA. Three individuals were sampled: a representative healthy control (top row); a patient with representative primary SARS-CoV-2 infection at day 9 and 13 post-onset of symptoms (highlighted by green bar); and reinfected patient at day 14, 18 and 42 (pending) post-onset of symptoms (highlighted by pink bar). Serostatus and days post symptoms onset are given on the right y-axis. Columns indicate the class of each IGH sequence with the IGHV gene indicated on the x-axis. The left y-axis indicates CDR-H3 length in amino acids (AA). Dots indicate B cell clonal lineages. Point color indicates median IGHV somatic hypermutation frequency for each clone, and point size indicates the number of reads in the clone. Points are jittered to decrease over-plotting. Panel B: The bar plot summarizes single-B cell transcriptome data indicating the antibody isotype expressed by B cells in the reinfected patient’s blood, plotted as the frequency of usage of each isotype.

Patient Population & PCR Testing

“Re-positivity” was defined as repeat SARS-CoV-2 PCR positive after negative testing in patients with initially PCR-confirmed COVID-19. To understand the duration of shedding and phenotypes of re-positivity, we analyzed a database of all SARS-CoV-2 PCR testing for patients with nasopharyngeal samples sent from the emergency departments or hospitals of Swedish Health System in Seattle, WA. Semi-quantitative real time polymerase chain reaction (rt-PCR) testing reported as cycle thresholds (Ct) were performed on the Xpert® Xpress SARS-CoV-2 test on the GeneXpert Infinity (Cepheid, Sunnyvale, CA). Hospital policies discouraged unnecessary testing, but the decision to test was left to individual providers. Retesting was often requested by congregate living facilities prior to receiving patients following hospitalization. Discontinuation of transmission-based isolation synchronized with the CDC interim guidance.²² Descriptive statistics were performed on population shedding dynamics.

Virologic and Immunologic Analyses

Viral sequencing in March was performed via rapid metagenomic next-generation sequencing (NGS),²³ and in July was modified from the multiplexed PCR amplicon NGS method using the ARTIC V3 primers.²⁴ SARS-CoV-2 clade designations and phylogenetic analyses were produced using NextStrain.²⁵ Serological testing used enzyme-linked immunosorbent assay (ELISA) for anti-spike, anti-RBD, and anti-N IgG, IgM and IgA antibodies, as well as a functional assay for antibodies that block binding of RBD to an ACE2 fusion protein.¹³ Functional nAbs were measured with a cell-culture based assay using pseudoviruses containing either the D614 or the G614 epitopes in spike.²¹ Immunoglobulin heavy chain (IGH) genes expressed by peripheral blood B cells were sequenced with amplicon libraries produced for each isotype,¹⁹ and paired IGH and light chain sequences were determined with single B cell transcriptome analysis.¹⁹ All assays are described in depth (Supplemental Methods).

Ethical Approval

The Providence St. Joseph’s Health IRB approved the study (STUDY2020000175). Informed consent was waived for use of residual samples and population clinical data (STUDY2020000143).